Clinical Trial Update: A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of vemurafenib and obinutuzumab versus cladribine and rituximab in hairy cell leukemia, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Gazyva (Obinutuzumab)
• Leustatin (cladribine)
• Rituxan (rituximab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hairy Cell Leukemia | Phase 2 | Status: RECRUITING